Urology

Cost variation among urologists: Can we trim the fat?"All the surgeons I know think that while they may not be the best in the world at what they do, they are clearly above average (think Lake Wobegon, but as adults). Hence, it can be a little disconcerting when data is produced that suggests that at least half of us have room for improvement," writes Henry Rosevear, MD.
Survey: Urologists lack knowledge, training in transgender careWhile urologists are generally comfortable discussing patients’ sexual orientation, they report that both their knowledge of care of transgender patients and training in such care are lacking.
If disaster strikes, is your practice prepared?A month after Hurricane Harvey’s aftermath, Houston-based urologist Steven Canfield, MD, says his practice is still having to reschedule operating room times to help out with the hurricane-induced OR shortage.
Shock waves may change future of ED therapyIt’s hard to argue against an erectile dysfunction treatment that is potentially disease modifying, is noninvasive, and seems to do no harm. The treatment, low-intensity shock wave therapy, has yet to earn the FDA’s approval but is widely used in other countries. Early results from ongoing U.S. trials are promising.
PSA screening: Do you discuss it with primary care docs?We asked several urologists about whether they advocate for PSA screening to primary care physicians in their area.
Bladder Ca subtypes ID’d, may yield personalized therapiesResearchers from The Cancer Genome Atlas Research Network have outlined five distinct expression subtypes of muscle-invasive bladder cancer, each of which may be targetable by different treatments.
Cisplatin nanoparticles appear efficacious for treating NMIBCThe use of intravesical cisplatin nanoparticles reduces cancer cell proliferation while limiting drug absorption beyond the bladder barrier, according to early findings.
Sacral neuromodulation, botulinum show equal efficacyIn patients with refractory urgency urinary incontinence (UUI), sacral neuromodulation (InterStim) and onabotulinumtoxinA (Botox) produce similar reductions in mean daily UUI episodes, according to 24-month follow-up data on patients treated in a randomized trial.
PCa active surveillance trends revealed in ‘real-world’ studyNearly three-fourths of men with very low-risk prostate cancer underwent active surveillance as a primary therapy, according to a study presented at the LUGPA annual meeting in Chicago.
Prevent burnout by restoring professional fulfillment“The answer is to remove the barriers and frustrations that are causing burnout so that physicians can focus on their role as care providers,” advises Paul DeChant, MD, MBA.